



Supplementary Figure 1 – Summary of the screening of compounds against iron mediated neurotoxicity.

The number of neurons left following exposure to each compound was normalized to the number of neurons of the respective control condition. The corresponding iron situation was also normalized to the respective control (red). Compounds which exhibit significant protection are highlighted in yellow and marked (X). Shown are the means \pm SEM of 1-4 experiments, each performed in quadruplicates. Supplementary figures 1-7 comprise the complete list of medications tested for the iron-mediated neurotoxicity screening.




Supplementary Figure 2 – Summary of the screening of compounds against iron mediated neurotoxicity.

The number of neurons left following exposure to each compound was normalized to the number of neurons of the respective control condition. The corresponding iron situation was also normalized to the respective control (red). Compounds which exhibit significant protection are highlighted in yellow and marked (X). Shown are the means \pm SEM of 1-4 experiments, each performed in quadruplicates. Supplementary figures 1-7 comprise the complete list of medications tested for the iron-mediated neurotoxicity screening.




Supplementary Figure 3 – Summary of the screening of compounds against iron mediated neurotoxicity.

The number of neurons left following exposure to each compound was normalized to the number of neurons of the respective control condition. The corresponding iron situation was also normalized to the respective control (red). Compounds which exhibit significant protection are highlighted in yellow and marked (X). Shown are the means \pm SEM of 1-4 experiments, each performed in quadruplicates. Supplementary figures 1-7 comprise the complete list of medications tested for the iron-mediated neurotoxicity screening.




Supplementary Figure 4 – Summary of the screening of compounds against iron mediated neurotoxicity.


The number of neurons left following exposure to each compound was normalized to the number of neurons of the respective control condition. The corresponding iron situation was also normalized to the respective control (red). Compounds which exhibit significant protection are highlighted in yellow and marked (X). Shown are the means \pm SEM of 1-4 experiments, each performed in quadruplicates. Supplementary figures 1-7 comprise the complete list of medications tested for the iron-mediated neurotoxicity screening.



Supplementary Figure 5 – Summary of the screening of compounds against iron mediated neurotoxicity. The number of neurons left following exposure to each compound was normalized to the number of neurons of the respective control condition. The corresponding iron situation was also normalized to the respective control (red). Compounds which exhibit significant protection are highlighted in yellow and marked (X). Shown are the means \pm SEM of 1-4 experiments, each performed in quadruplicates. Supplementary figures 1-7 comprise the complete list of medications tested for the iron-mediated neurotoxicity screening.



Supplementary Figure 6 – Summary of the screening of compounds against iron mediated neurotoxicity. The number of neurons left following exposure to each compound was normalized to the number of neurons of the respective control condition. The corresponding iron situation was also normalized to the respective control (red). Compounds which exhibit significant protection are highlighted in yellow and marked (X). Shown are the means \pm SEM of 1-4 experiments, each performed in quadruplicates. Supplementary figures 1-7 comprise the complete list of medications tested for the iron-mediated neurotoxicity screening.



Supplementary Figure 7 – Summary of the screening of compounds against iron mediated neurotoxicity.

The number of neurons left following exposure to each compound was normalized to the number of neurons of the respective control condition. The corresponding iron situation was also normalized to the respective control (red). Compounds which exhibit significant protection are highlighted in yellow and marked (X). Shown are the means \pm SEM of 1-4 experiments, each performed in quadruplicates. Supplementary figures 1-7 comprise the complete list of medications tested for the iron-mediated neurotoxicity screening.